trial · primary record
Biospecimen Collection
Recurrent Multiple Myeloma
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 26 |
| Primary completion | 2026-12-31 |
| Primary endpoint | Recommended phase 2 dose (RP2D) of iberdomide when combined with teclistamab |
| Registry ID | NCT06465316 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:33:11.661Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06465316
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.